Previous 10 | Next 10 |
SAN DIEGO , April 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline data from a Phase 1 clinical study evaluating controlled-release delivery profiles (CR) for its investigational agent, etrasimod, a highly selective, once-daily, or...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Outperform rating and $54 (88% upside) price target at BMO. More news on: Apellis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
SAN DIEGO , March 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company. "We are honored to have Jim as an advisor to Arena. In a rapidly evolving...
Today, we will see why Arena Pharmaceuticals (ARNA) is an attractive pick in March 2020. Company overview Arena Pharmaceuticals is a biopharmaceutical company with four clinical-stage assets, Etrasimod, Olorinab, APD418, and Ralinepag partnership, which are being evaluated across eight d...
Quick Take NLS Pharmaceutics ( NLSP ) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement . The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders. NLSP expects to begin...
If you think investors made big money from cannabis stocks, you had better be ready to start buying psychedelic medicine stocks! Psychedelic medicine involves the use of psychedelic substances such as psilocybin (the chemical in magic mushrooms), MDMA, LSD, and ketamine to treat people with de...
The following slide deck was published by Arena Pharmaceuticals, Inc. in conjunction with this Read more ...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading
Arena Pharmaceuticals, Inc. (ARNA) Q4 2019 Results Earnings Conference Call February 26, 2020 05:00 PM ET Company Participants Kevin Lind - Chief Financial Officer Amit Munshi - Chief Executive Officer Preston Klassen - Executive Vice President and Chief Medical Officer Confer...
Arena Pharmaceuticals (NASDAQ: ARNA ): Q4 GAAP EPS of -$1.76 misses by $0.22 . Revenue of $3M (-65.5% Y/Y) beats by $1.44M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...